Why the study?
What is the long-term durability and rate of structural valve dysfunction of the Mitroflow A12 pericardial bioprosthesis in patients over 70 years old?
Population
491 patients over the age of 70 years who received an aortic Mitroflow A12 bioprosthesis implantation
Design
Cohort
Follow-up
up to 10 years
Key result
In patients over 70 years old, the Mitroflow A12 pericardial bioprosthesis showed suboptimal durability, with freedom from structural valve dysfunction of 95% at 5 years and 55.8% at 10 years.
Authors
Loading...
Caution advised selecting Mitroflow A12 for patients >70; observational data leaves open need for comparative durability trials.
Cohort (n=491)
What is the long-term durability and rate of structural valve dysfunction of the Mitroflow A12 pericardial bioprosthesis in patients over 70 years old?
The Mitroflow A12 pericardial bioprosthesis demonstrates suboptimal long-term durability in elderly patients, with high rates of structural valve deterioration by 10 years.
Álvarez et al. (2009) conducted a cohort in Aortic valve replacement (n=491). Mitroflow A12 pericardial bioprosthesis was evaluated on Freedom from structural valve dysfunction (SVD) at 10 years. In patients over 70 years old, the Mitroflow A12 pericardial bioprosthesis showed suboptimal durability, with freedom from structural valve dysfunction of 95% at 5 years and 55.8% at 10 years.